SecBot SecBot
SC 13G/A ·Filed Nov 13, 2026

SRPT

Sarepta Therapeutics, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed3d 17h ago SEC0001167557-26-000255
Passive stake amendment
Actionable Insight • Neutral

The sharp reduction in AQR's disclosed stake from 7.4% to 1.31% suggests significant selling or a change in reporting methodology. Monitor for any further 13G amendments or a potential conversion to a 13D filing if AQR's intent shifts.

DirectionNeutral
Confidencemedium
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$16.07
T+0 close · Nov 13, 2026 · via day close
Latest settled
−5.85%
T+1 · $15.13
Vs SPY
−3.94%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $16.07entry
  2. T+1 · 19h ago −5.85%α −3.94% · $15.13
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

AQR Capital Management LLC filed an amended Schedule 13G disclosing a 1.31% passive stake in Sarepta Therapeutics as of September 30, 2026, down from its prior 7.4% stake reported three days earlier. The filing confirms passive intent and no control-related purpose.

Key Financial Metrics

Stake
1.31%
Investor
AQR Capital Management LLC
Investor Type
hedge fund

Key Facts

  • AQR Capital Management LLC disclosed beneficial ownership of 1,386,343 shares of Sarepta common stock, representing 1.31% of shares outstanding as of September 30, 2026.
  • The stake includes Convertible Notes representing 990,669 shares of common stock.
  • This filing is an amendment to the prior Schedule 13G filed November 10, 2026, which disclosed a 7.4% stake.
  • AQR certifies passive investment intent with no purpose of changing or influencing control of the issuer.

Financial Impact

AQR reduced its reported stake from 7.4% to 1.31%, a decrease of approximately 6.1 percentage points.

ownership_percentage

Risk Factors

  • AQR's reduced stake could signal reduced institutional confidence, though the passive filing intent remains unchanged.
  • The stake includes convertible notes, which may complicate the true economic exposure.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
39% bullish (31 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13G/A Filing (Primary)0001167557-26-000255
Document: 0001167557-26-000255-index.html0001167557-26-000255
Document: 0001167557-26-000255.txt0001167557-26-000255

US Market Status

Market Closed · Opens in 7h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026